Song Li-ping, Li Yue-ping, Qiu Shu-dong, Wang Ning
Department of Radiation Therapy, The First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an 710061, China.
Zhonghua Zhong Liu Za Zhi. 2010 Jan;32(1):10-6.
To construct a recombinant lentivirus vector containing fusion gene NT4-p53(N15)-Ant and transfer it into HepG2 cancer cells for gene therapy.
The gene of p53(N15)-Ant was obtained by T-vector method. After restriction enzyme digestion, the interest gene of p53(N15)-Ant was inserted in pBV220/NT4 vector and fusion gene of NT4-p53(N15)-Ant was subcloned into the plasmid of lentivirus and cotransferred into HEK-293 cells with helper plasmid. The recombinant lentivirus was produced by homologous recombination of the above mentioned two plasmids in HEK-293 cells and its titer was measured by plaque-forming. The expression of LV. NT4-p53-Ant in transfected HepG2 cells was finally confirmed by reverse transcription polymerase chain reaction (RT-PCR) procedure. The effect of LV. NT4-p53(N15)-Ant on HepG2 cells was measured by a colorimetric 3-[4,5-dimethyl thiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay. The inhibition effect on HepG2 cells of LV. NT4-p53(N15)-Ant and its potential mechanism was detected by light microscopy, electron microscopy, MTT, LDH-release assay and annexin V-PI double staining.
The gene of p53(N15)-Ant was confirmed by restriction enzyme digestion and DNA sequencing. High titer of the recombinant lentivirus was obtained by homologous recombination in HEK-293 cell lines (1 x 10(11) pfu/ml), and the expression of NT4-p53(N15)-Ant gene in HepG2 cells was confirmed by RT-PCR. The viability of HepG2 cells was decreased to 83.4%, 46.9% and 33.9%, at 24 h, 48 h and 72 h, respectively, after infection by LV. NT4-p53(N15)-Ant. Compared with the LV. EGFP control group, there were significant differences (P < 0.01). The LDH level in HepG2 cells infected by LV. NT4-p53(N15)-Ant at 48 h, 72 h and 96 h after infection was 682 IU/L, 815 IU/L and 979 IU/L, respectively, significantly increased than that in the LV. EGFP group (P < 0.01), indicating the cell membrane destruction.
The recombinant lentivirus vector encoding gene NT4-p53(N15)-Ant is successfully constructed in this experiment by molecular cloning and recombination in vitro techniques, and the results suggested that this fusion gene has an anti-tumor effect, which provides the basis for further research on recombinant adenovirus for cancer gene therapy.
构建含融合基因NT4-p53(N15)-Ant的重组慢病毒载体,并将其转入肝癌细胞HepG2进行基因治疗。
采用T载体法获取p53(N15)-Ant基因。经限制性内切酶酶切后,将p53(N15)-Ant目的基因插入pBV220/NT4载体,把NT4-p53(N15)-Ant融合基因亚克隆至慢病毒质粒,并与辅助质粒共转入HEK-293细胞。通过上述两种质粒在HEK-293细胞中的同源重组产生重组慢病毒,采用空斑形成法测定其滴度。最终通过逆转录聚合酶链反应(RT-PCR)程序证实转染的HepG2细胞中LV.NT4-p53-Ant的表达。采用比色法3-[4,5-二甲基噻唑-2-基]-2,5-二苯基四氮唑溴盐(MTT)法检测LV.NT4-p53(N15)-Ant对HepG2细胞的作用。通过光学显微镜、电子显微镜、MTT、乳酸脱氢酶(LDH)释放试验和膜联蛋白V-碘化丙啶(PI)双染法检测LV.NT4-p53(N15)-Ant对HepG2细胞的抑制作用及其潜在机制。
经限制性内切酶酶切和DNA测序证实p53(N15)-Ant基因。通过HEK-293细胞系中的同源重组获得高滴度的重组慢病毒(1×10¹¹ pfu/ml),并通过RT-PCR证实HepG2细胞中NT4-p53(N15)-Ant基因的表达。LV.NT4-p53(N15)-Ant感染后,HepG2细胞在24 h、48 h和72 h时的活力分别降至83.4%、46.9%和33.9%。与LV.绿色荧光蛋白(EGFP)对照组相比,差异有统计学意义(P<0.01)。LV.NT4-p53(N15)-Ant感染后48 h、72 h和96 h时,HepG2细胞中的LDH水平分别为682 IU/L、815 IU/L和979 IU/L,明显高于LV.EGFP组(P<0.01),表明细胞膜被破坏。
本实验通过体外分子克隆和重组技术成功构建了编码基因NT4-p53(N15)-Ant的重组慢病毒载体,结果表明该融合基因具有抗肿瘤作用,为进一步研究重组腺病毒用于癌症基因治疗提供了依据。